"Lipocalin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipocalin of approximately 200 amino acids that functions as an iron transporter and is expressed by cells of BONE MARROW and many other cells with secretory functions. It is involved in APOPTOSIS and may function to limit pathogenic bacterial growth as part of the INNATE IMMUNE RESPONSE.
| Descriptor ID |
D000071068
|
| MeSH Number(s) |
D12.776.124.050.475 D12.776.157.469.325 D12.776.624.664.700.123
|
| Concept/Terms |
Lipocalin-2- Lipocalin-2
- Lipocalin 2
- NGAL Protein
- Oncogene 24p3 Protein
- Siderocalin Protein
- Neutrophil Gelatinase-Associated Lipocalin
- Neutrophil Gelatinase Associated Lipocalin
- Lipocalin-2 Protein
- Lipocalin 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "Lipocalin-2".
Below are MeSH descriptors whose meaning is more specific than "Lipocalin-2".
This graph shows the total number of publications written about "Lipocalin-2" by people in this website by year, and whether "Lipocalin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipocalin-2" by people in Profiles.
-
Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury. Biosens Bioelectron. 2026 Nov 15; 312:118990.
-
A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014; 39(6):543-52.
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
-
Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer. 2011 Jun 01; 117(11):2408-18.
-
Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011 Feb; 38(2):325-33.
-
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008 Aug 01; 68(15):6100-8.
-
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 2008 Oct 16; 27(47):6110-9.
-
Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care. 2007; 11(4):R84.